The study employed molecular docking techniques to analyze the interaction between the STAMBPL1 protein and commonly used first-line drugs for clinical liver cancer (including sorafenib, regorafenib, lenvatinib, and cabozantinib). Here, STAMBPL1 is linked to liver cancer.